Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
A novel direction on exploring metabolic beneficial effect of dietary interventions- involving gut microbiome, the gut hormone GLP-1, and the liver hormone FGF21
EF 2023-24
Résumé
Dietary polyphenols (DPs) possess metabolic beneficial effects in animals and human subjects. Among them, resveratrol (REV) intervention (REV-I) reduces blood glucose and lipid levels and improves insulin sensitivity, making it a candidate for the "treatment" and prevention of diabetes, fatty liver diseases and their cardiovascular complications. However, the mechanism remains unclear. We reported that the bacteria residing in the gut (i.e., gut microbiome) is the main target of REV-I. We have long term track record in exploring functions of diabetes drugs known as GLP-1 receptor agonists (GLP-1RA, i.e., Liraglutide). Liraglutide was shown to target hepatic hormone FGF21 and FGF21 is also the common target of GLP-1RAs and DPs. FGF21 analogues attenuate blood lipid level and improve insulin sensitivity in several clinical trials. Based on those findings, I plan to connect the dots and hypothesize that mechanisms underlying beneficial effects of DPs are mediated via changes in the gut microbiome, this in turn changes gut environment and hormones like GLP-1 and FGF21 by either altering their production or function. To test this, I will utilize cellular and mouse models to address how REV-I works with gut microbiome to regulate the function of GLP-1-producing cells (Aim I). Furthermore, I will also determine whether liver hormone FGF21 is required for REV-I to exert its beneficial effects (Aim II). For the past 2-3 decades, beneficial effects of DPs have been extensively studied, yet very little is known about how they work. Our findings on the interaction between DPs and gut microbiome lay the groundwork and inspire me to further study this. Such study will make fundamental changes in the understanding of DPs, especially by bringing "seemly unrelated" players such as GLP-1 and FGF21. Examining such interaction between DPs, gut microbiome and metabolic hormones will warrant novel therapeutic approaches for future metabolic disease treatment and prevention.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
496532
Name
Feng Jia Nuo
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Nutrition, Metabolism and Diabetes
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A novel direction on exploring metabolic beneficial effect of dietary interventions- involving gut microbiome, the gut hormone GLP-1, and the liver hormone FGF21
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Dietary Polyphenol; Extra-Pancreatic; Fgf21; Glp-1/Fgf21 Axis; Glp-1/Glp-1r; Gut Microbiome; Liver Diseases; Obesity; Resveratrol; Type 2 Diabetes
Abstract
Dietary polyphenols (DPs) possess metabolic beneficial effects in animals and human subjects. Among them, resveratrol (REV) intervention (REV-I) reduces blood glucose and lipid levels and improves insulin sensitivity, making it a candidate for the "treatment" and prevention of diabetes, fatty liver diseases and their cardiovascular complications. However, the mechanism remains unclear. We reported that the bacteria residing in the gut (i.e., gut microbiome) is the main target of REV-I. We have long term track record in exploring functions of diabetes drugs known as GLP-1 receptor agonists (GLP-1RA, i.e., Liraglutide). Liraglutide was shown to target hepatic hormone FGF21 and FGF21 is also the common target of GLP-1RAs and DPs. FGF21 analogues attenuate blood lipid level and improve insulin sensitivity in several clinical trials. Based on those findings, I plan to connect the dots and hypothesize that mechanisms underlying beneficial effects of DPs are mediated via changes in the gut microbiome, this in turn changes gut environment and hormones like GLP-1 and FGF21 by either altering their production or function. To test this, I will utilize cellular and mouse models to address how REV-I works with gut microbiome to regulate the function of GLP-1-producing cells (Aim I). Furthermore, I will also determine whether liver hormone FGF21 is required for REV-I to exert its beneficial effects (Aim II). For the past 2-3 decades, beneficial effects of DPs have been extensively studied, yet very little is known about how they work. Our findings on the interaction between DPs and gut microbiome lay the groundwork and inspire me to further study this. Such study will make fundamental changes in the understanding of DPs, especially by bringing "seemly unrelated" players such as GLP-1 and FGF21. Examining such interaction between DPs, gut microbiome and metabolic hormones will warrant novel therapeutic approaches for future metabolic disease treatment and prevention.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Feng, Jia Nuo
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~